Forced Biosimilar Switching: What Rheumatology Practices Are Experiencing
Forced biosimilar switching can create significant operational challenges for rheumatology practices. Explore how payer-driven changes affect prior authorization, patient communication, purchasing, reimbursement, product availability, and continuity of treatment.
Biosimilars have become an established part of rheumatology treatment, giving providers additional biologic options and creating greater competition within the specialty pharmaceutical market. For practices managing rheumatoid arthritis and other inflammatory diseases, however, the growth of biosimilars has also introduced a new operational challenge: payer-driven or forced switching.
A forced biosimilar switch generally occurs when an insurer, pharmacy benefit manager, or formulary policy requires a patient to move from a reference biologic to a biosimilar, or from one biosimilar to another, for reasons that are not driven by a new clinical decision from the treating rheumatologist.
That distinction matters. The FDA’s biosimilar information for healthcare professionals explains that approved biosimilars are highly similar to their reference products and have no clinically meaningful differences in safety or effectiveness. The operational concern for practices is therefore not simply whether biosimilars are appropriate treatment options. It is how repeated payer-driven changes affect prior authorization, patient communication, specialty drug purchasing, reimbursement, scheduling, and continuity of treatment.
In 2026, the American College of Rheumatology reported that practices were experiencing treatment disruptions associated with payer and specialty pharmacy-driven biosimilar switching, including repeated switches, medication shortages, higher patient out-of-pocket costs, and treatment delays.
What Is Forced Biosimilar Switching?
A biosimilar switch can happen for several reasons. A rheumatologist and patient may decide that changing therapy is appropriate, an insurer may change its preferred formulary product, or an interchangeable biosimilar may be substituted at the pharmacy when permitted under state law.
Forced or non-medical switching generally refers to a situation in which the change is primarily driven by coverage, contracting, formulary, or other payer considerations rather than a new treatment decision initiated by the clinician.
The American College of Rheumatology draws an important distinction here. Its official position statement on biosimilars supports the use of biosimilars as a way to reduce costs and improve access to biologic therapy, while opposing insurer-mandated switching and expressing concern about frequent non-medical switches.
That means supporting biosimilar adoption and questioning mandatory switching are not contradictory positions.
For rheumatology practices, the issue is often whether the treatment change can be implemented without creating unnecessary administrative, financial, or access problems for the patient and practice.
Why Are More Rheumatology Patients Being Switched?
As more biosimilars enter the U.S. market, health plans have more products available when determining preferred formulary options.
FDA’s current biosimilar product database continues to expand, including products relevant to inflammatory and rheumatologic conditions. In May 2026, for example, FDA approved biosimilars to Simponi and Simponi Aria, adding another set of options to a market that already includes multiple biosimilars for biologics used across rheumatology.
Greater competition can benefit the healthcare system, but it also means payer preferences can change.
A health plan may designate one biosimilar as preferred based on factors such as:
- Contracting arrangements
- Drug acquisition economics
- Manufacturer rebates
- Formulary strategy
- Pharmacy benefit design
- Medical benefit policies
- Specialty pharmacy relationships
- Changes in product availability
When a payer changes its preferred product, a rheumatology practice may suddenly need to transition a large group of established patients at the same time.
That can turn one formulary decision into dozens or hundreds of individual administrative workflows.
Practices Are Managing New Prior Authorizations
One of the most immediate challenges is prior authorization.
The ACR’s current insurance advocacy resources state that many health plans requiring patients to move from an originator biologic to a biosimilar are also requiring practices to complete a new prior authorization for the replacement medication. ACR reports that these requirements are creating significant administrative burden, particularly when payers request additional medical records.
For a single patient, that may mean another authorization request.
For a large community rheumatology practice, one formulary change can mean repeating that process across a substantial patient population.
Staff may need to:
- Identify affected patients
- Verify the newly preferred product
- Submit new prior authorizations
- Provide clinical records
- Coordinate specialty pharmacy requirements
- Confirm product availability
- Communicate the change to patients
- Update infusion schedules
- Review specialty drug purchasing arrangements
That work comes on top of the existing administrative responsibilities associated with physician-based infusion.

Repeated Switching Creates Additional Complexity
The challenge becomes greater when the switch does not happen only once.
As payer contracts and preferred products change, a patient may move from a reference biologic to one biosimilar and later be required to move to another biosimilar.
In July 2026, the ACR reported through The Rheum Advocate that rheumatology practices were reporting repeated forced switches tied to payer and specialty pharmacy policies.
Each additional switch can restart parts of the workflow.
Practices may need to revisit authorization, patient education, acquisition arrangements, product availability, reimbursement, and scheduling.
Repeated switching can also create communication challenges. A patient may have already become comfortable with one biosimilar only to receive notice that the payer now prefers another.
Even when the products meet FDA biosimilar standards, the practice still needs to explain why another change is occurring and what it means for the patient’s treatment.
Patient Communication Becomes More Important
Patients may understandably have questions when they are told that a biologic medication is changing despite doing well on their existing therapy.
Common questions can include:
- Why is my medication changing?
- Did my rheumatologist recommend the switch?
- Is the biosimilar as effective?
- Is it safe to switch?
- Will my infusion schedule change?
- Will my out-of-pocket cost change?
- Could my insurance company switch it again?
FDA has tried to address some of these concerns through its education on switching between biosimilars and reference products. FDA researchers reviewed switching data and found no meaningful increase in serious safety outcomes associated with switching between reference products and biosimilars, including in data involving multiple switches.
That evidence can help rheumatology teams reassure patients about FDA-approved biosimilars.
At the same time, the ACR’s patient guidance states that the decision to start or switch to a biosimilar should involve discussion with the rheumatology healthcare provider.
The clinical evidence around biosimilar switching and the policy question of who initiates that switch are therefore separate issues.
Specialty Drug Purchasing Can Change Overnight
For practices operating in-office infusion programs, a formulary switch also affects pharmaceutical purchasing.
A rheumatology practice may already have a specialty drug purchasing strategy built around particular biologics or biosimilars. That strategy may include distributor relationships, GPO contracts, manufacturer agreements, inventory levels, and expected patient utilization.
When a payer requires a different biosimilar, the purchasing team may need to determine:
- Is the new product available through the current distributor?
- Does an existing GPO contract cover it?
- What GPO pricing applies?
- Is the practice eligible for the manufacturer program?
- Does class of trade affect contract eligibility?
- Is the medication in stock?
- Does the payer require a specialty pharmacy instead?
- What reimbursement will the practice receive?
The switch may therefore be a payer decision, but much of the implementation burden falls on the provider.
For practices administering high-cost specialty drugs, this can create significant financial exposure if purchasing and reimbursement are not evaluated before the transition takes place.

Reimbursement Can Become a Major Barrier
A payer may require a specific biosimilar without necessarily accounting for what an independent practice actually pays to acquire that product.
The ACR currently identifies what it calls “underwater biosimilars” as an active reimbursement issue. Its insurance advocacy materials state that some payer formularies require biosimilars for which reimbursement falls below acquisition cost for independently owned rheumatology practices.
That creates a difficult position for practices using buy-and-bill.
Under buy-and-bill, the practice purchases the medication before treatment, administers it, and then seeks reimbursement. If the reimbursement is lower than the acquisition cost, the practice can lose money each time it provides the payer-required drug.
This is why GPO pricing, contract pricing, specialty drug purchasing, and payer reimbursement need to be evaluated together.
A biosimilar can be lower-cost at a system level while still creating unsustainable economics for an individual practice depending on how the purchasing and reimbursement arrangements are structured.
The issue has attracted broader attention. In June 2026, ACR reported that members of Congress had urged federal officials to address Medicare payment situations where certain infused biosimilars were reimbursed below practice acquisition costs.
Product Shortages Can Make Mandatory Switching Harder
Payer policies also assume that the preferred biosimilar is actually available.
That assumption can break down when utilization increases quickly or supply becomes constrained.
A recent example involved Tyenne, a tocilizumab biosimilar. In July 2026, the ACR reported a widespread shortage associated with increased demand and intermittent out-of-stock periods. Its medication resources for rheumatology practices advised affected practices to review patient rosters, consider appropriate alternatives, and pursue insurance overrides when needed.
For a practice dealing with a mandated biosimilar, a shortage can create a chain of additional problems.
The practice may need to identify an alternative product, determine whether the payer covers it, submit another prior authorization or formulary exception, confirm specialty drug purchasing arrangements, and potentially reschedule treatment.
This illustrates why formularies, distribution, reimbursement, and product availability cannot be managed independently from one another.
Treatment Delays Are a Real Operational Concern
Every additional step creates another opportunity for treatment to be delayed.
A patient may wait while the practice completes a new authorization. A product may be unavailable. The insurer may require a different specialty pharmacy. The practice may need an exception because the mandated product is financially underwater. A patient may face a higher out-of-pocket obligation.
In its July 2026 update, ACR specifically connected medication shortages, repeated forced switches, and increased patient costs with treatment delays reported by rheumatology practices.
For patients managing chronic inflammatory or autoimmune diseases, continuity of access is an important consideration.
This is why the operational details surrounding a biosimilar switch matter even when the underlying biosimilar is clinically appropriate.

Specialty Pharmacy Requirements Can Complicate the Switch Further
Some payer-driven biosimilar changes can also involve a change in acquisition channel.
A practice that normally purchases an infused biologic under buy-and-bill may be told that the payer’s preferred biosimilar must instead be obtained through a designated specialty pharmacy.
That can create two changes simultaneously:
- The medication changes.
- The pharmaceutical purchasing pathway changes.
The practice may no longer be purchasing the product through its normal distributor or applicable infusion GPO contract. Instead, the specialty pharmacy may ship a patient-specific medication to the office for administration.
This can affect inventory control, scheduling, GPO pricing, pharmaceutical contracting, and practice reimbursement.
For rheumatology practices already managing multiple payer policies, the combination of forced switching and specialty pharmacy acquisition requirements can make individual patient workflows significantly different even when patients are receiving treatment for similar conditions.
Biosimilars and Interchangeability Are Not the Same Thing
Another source of confusion involves the FDA designation of “interchangeable.”
All FDA-approved biosimilars must demonstrate that they are highly similar to the reference product and have no clinically meaningful differences in safety and effectiveness.
An interchangeable biosimilar has met additional statutory requirements related to pharmacy-level substitution. Depending on state law, that designation can allow a pharmacist to substitute the interchangeable product for the reference biologic without contacting the prescriber.
FDA emphasizes in its guidance on biosimilar interchangeability that an interchangeable biosimilar is not inherently safer or more effective than a biosimilar without that designation.
That distinction is important when discussing forced switching.
A payer formulary decision requiring a physician-administered biosimilar is not necessarily the same thing as pharmacy-level substitution involving an FDA-designated interchangeable product.
Practices need to understand what is driving the change and what authorization, purchasing, and prescribing requirements apply.
The Biosimilar Market Is Still Expanding
Rheumatology practices should expect biosimilar management to remain a significant operational issue.
FDA continues to approve new products, including biosimilars relevant to drugs used in inflammatory diseases. The agency’s expanding approval list means providers, payers, manufacturers, and specialty pharmacies will have more products to evaluate over time.
More competition may create meaningful opportunities to reduce costs and improve access.
It can also create more contracting combinations, payer preferences, manufacturer programs, and specialty pharmaceutical distribution pathways.
The challenge for practices is building processes flexible enough to accommodate those changes without allowing each formulary update to become a major operational disruption.
What Rheumatology Practices Should Monitor
Practices managing biologic and biosimilar therapies should monitor both clinical developments and the business infrastructure surrounding them.
Important areas include:
- Payer formulary changes
- New biosimilar approvals
- Required product switches
- Prior authorization requirements
- Specialty pharmacy mandates
- Product availability
- GPO contract changes
- GPO pricing
- Acquisition cost
- Reimbursement
- Manufacturer programs
- Patient out-of-pocket costs
- State substitution requirements
The ACR maintains a dedicated Biosimilar Resource Center with provider resources, policy statements, educational materials, and information about coverage considerations.
Keeping payer and purchasing data current can help practices identify potential problems before a scheduled infusion is affected.
How a Specialty Healthcare GPO Can Support the Purchasing Side
A specialty healthcare GPO does not control payer formularies and cannot determine whether an insurer requires a biosimilar switch.
Its role is on the pharmaceutical purchasing and contracting side of specialty care.
For qualifying physician practices and other non-acute providers, an infusion GPO or specialty drug GPO can help provide greater visibility into:
- Manufacturer GPO contracts
- GPO pricing
- Contract eligibility
- Specialty drug purchasing
- Class of trade
- Product availability
- Manufacturer programs
- Roster management
- Pharmaceutical contract changes
That visibility becomes particularly useful when a payer changes its preferred biosimilar.
The practice still needs to determine whether the new therapy is covered and clinically appropriate, but it also needs to know how the product can be acquired and which purchasing agreement applies.
For pharmaceutical manufacturers, a GPO relationship can provide a more structured connection with specialty providers while improving visibility into participation and program performance across physician-based infusion and other alternative sites of care.
Preparing for Continued Biosimilar Switching
Biosimilars are an increasingly important part of rheumatology, and the growing number of treatment options has the potential to create greater competition and access.
The challenge for rheumatology practices is making sure the way those products are implemented does not create unnecessary disruption.
Forced or payer-driven switching can affect prior authorization, patient communication, specialty pharmacy requirements, GPO contracts, specialty drug purchasing, reimbursement, inventory, and treatment scheduling all at once.
The experience reported by rheumatology practices in 2026 shows why biosimilar adoption cannot be evaluated only by looking at clinical comparability or product price. The operational environment surrounding the therapy matters as well.
AlignedCareGPO helps support the pharmaceutical purchasing side of that environment by creating clearer connections between eligible specialty providers and manufacturer programs across non-acute and alternative sites of care.
As biosimilar competition continues to expand, better alignment between providers, manufacturers, payers, specialty pharmacies, distributors, and GPO programs can help turn increased product choice into more manageable and sustainable access.
Related Articles
What Anti-Amyloid Therapies Mean for Neurology Infusion Operations
Anti-amyloid therapies are reshaping neurology infusion by requiring coordinated systems for patient selection, imaging, medication access, monitoring, purchasing, and caregiver communication well beyond the infusion itself.
Why Immune Globulin Continues to Grow Across Home and Alternate-Site Infusion
Immune globulin continues to expand across home and alternate-site care as long-term treatment needs, greater patient flexibility, mature specialty pharmacy infrastructure, and evolving reimbursement create more ways to deliver IVIG and SCIG beyond traditional hospital settings.
IVIG and SCIG Market Trends Specialty Providers Should Watch
The immunoglobulin market is becoming more segmented as IVIG, conventional SCIG, and facilitated SCIG expand across different care settings, distribution channels, reimbursement models, and patient preferences.
Stay Informed.
Stay Better Aligned.
Explore how AlignedCareGPO helps create stronger alignment between manufacturers, members, specialty distribution, and program execution to drive greater value across specialty healthcare.